Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety

Endocrinol Metab Clin North Am. 2009 Mar;38(1):79-97. doi: 10.1016/j.ecl.2008.11.007.

Abstract

Statins, ezetimibe, and bile acid-binding resins can be used individually or in combination for lowering low-density lipoprotein cholesterol (LDL-C) levels. Statins are the most potent drugs for lowering LDL-C and are well tolerated in most patients. The addition of a bile acid sequestrant or ezetimibe to a statin produces additional LDL-C reduction allowing many patients to reach LDL-C targets. This article discusses the efficacy and safety of available statins, bile acid sequestrants, and ezetimibe in the treatment of hyperlipidemia.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Animals
  • Anticholesteremic Agents / administration & dosage
  • Anticholesteremic Agents / adverse effects
  • Anticholesteremic Agents / pharmacology
  • Anticholesteremic Agents / therapeutic use*
  • Azetidines / adverse effects
  • Azetidines / therapeutic use*
  • Bile Acids and Salts / metabolism*
  • Cholesterol, LDL / blood*
  • Drug Therapy, Combination
  • Ezetimibe
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Hyperlipidemias / blood
  • Hyperlipidemias / drug therapy
  • Hypolipidemic Agents / adverse effects
  • Hypolipidemic Agents / therapeutic use*
  • Lipoproteins, LDL / blood*
  • Niacin / therapeutic use

Substances

  • Anticholesteremic Agents
  • Azetidines
  • Bile Acids and Salts
  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypolipidemic Agents
  • Lipoproteins, LDL
  • Niacin
  • Ezetimibe